Details for New Drug Application (NDA): 215960
The generic ingredient in UTEBZI is tebipenem pivoxil hydrobromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the tebipenem pivoxil hydrobromide profile page.
Summary for 215960
| Tradename: | UTEBZI |
| Applicant: | Glaxosmithkline |
| Ingredient: | tebipenem pivoxil hydrobromide |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 215960
Generic Entry Date for 215960*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 215960
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960 | NDA | GlaxoSmithKline LLC | 0173-0956 | 0173-0956-76 | 10 BLISTER PACK in 1 CARTON (0173-0956-76) / 8 TABLET, FILM COATED in 1 BLISTER PACK (0173-0956-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE | ||||
| Approval Date: | Jun 17, 2026 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 17, 2036 | ||||||||
| Regulatory Exclusivity Use: | GENERATING ANTIBIOTIC INCENTIVES NOW | ||||||||
| Regulatory Exclusivity Expiration: | Jun 17, 2031 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Feb 6, 2038 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS CAUSED BY E. COLI, K. PNEUMONIAE, ECC, K. OXYTOCA, OR E. FAECALIS IN PATIENTS WHO HAVE LIMITED OR NO ALTERNATIVE ORAL TREATMENT OPTIONS WITH A TEBIPENEM PIVOXIL HBR SALT FORM OF CLAIM 2 OF US10889587 | ||||||||
Complete Access Available with Subscription
